IRON Disc Medicine Inc
Price Chart
Executive Summary
Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63.5M from $34.1M a year ago on higher R&D and SG&A costs. The key catalyst is the completed enrollment of the Phase 3 APOLLO trial for bitopertin in EPP, with topline data expected in Q4 2026, which could support an FDA resubmission by mid-2027.
Actionable Insight
The Q1 earnings beat is marginal and overshadowed by rising operating losses. The stock will trade on pipeline catalysts: watch for the FDA Type A meeting outcome in Q2 and the Phase 3 APOLLO topline data in Q4 2026, which are the primary value drivers. The $730M cash runway into 2029 removes near-term financing risk.
Key Facts
- Q1 2026 EPS of -$1.65 vs consensus -$1.73 (4.6% beat)
- Net loss widened to $63.5M from $34.1M YoY, driven by higher R&D ($45.9M vs $27.8M) and SG&A ($23.6M vs $12.2M)
- Cash, cash equivalents, and marketable securities of $730.2M, providing runway into 2029
- Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (183 patients); topline data expected Q4 2026
- Type A meeting with FDA scheduled for Q2 2026 to discuss bitopertin CRL response; potential FDA decision by mid-2027
- Updated Phase 2 data for DISC-0974 in MF anemia to be presented at ASCO in June 2026
- Phase 2 data for DISC-3405 in PV and Phase 1b data in SCD expected Q4 2026
Financial Impact
Net loss of $63.5M in Q1 2026 vs $34.1M in Q1 2025; cash burn of ~$61M in the quarter
Risk Factors
- Bitopertin Phase 3 APOLLO trial failure or disappointing topline data in Q4 2026
- FDA Type A meeting could result in additional clinical requirements, delaying bitopertin approval
- Rising operating expenses without near-term revenue could pressure valuation if pipeline milestones slip
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287684 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Press Release
| $68.51 awaiting T+5 | awaiting T+5 | — | $67.99 (−0.76%) |
|
Jun 9, 2026
5d ago
|
Press Release
| $67.50 awaiting T+5 | awaiting T+5 | — | $67.99 (+0.73%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $71.97 $67.00 | ▼ −6.91% | ▼ −4.16% | $67.99 (−5.53%) |
|
May 5, 2026
5w ago
|
8-K
| $67.59 $69.23 | ▲ +2.43% | ▲ +0.44% | $67.99 (+0.59%) |
|
May 5, 2026
5w ago
|
Press Release
| $67.59 $69.23 | ▲ +2.43% | ▲ +0.44% | $67.99 (+0.59%) |
|
Apr 13, 2026
9w ago
|
Insider Cluster
| $68.46 $71.41 | ▼ −4.31% | ▼ −1.01% | $67.99 (+0.69%) |
|
Feb 26, 2026
15w ago
|
8-K
| $67.91 $60.34 | ▲ +11.15% | ▲ +10.02% | $67.99 (−0.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access